Ozempic, a medication used to improve blood sugar control in adults with type 2 diabetes, has been potentially linked to reduced meal portions. The drug's active ingredient is semaglutide, which works by mimicking the body's natural hormone, GLP-1, to control blood sugar levels.

According to a study published in the journal Diabetes, Obesity and Metabolism, semaglutide was found to reduce appetite and lead to weight loss in patients with obesity [1]. The study suggests that this effect could be due to the drug's impact on the areas of the brain responsible for appetite regulation. As a result, patients may experience a decrease in food intake and portion sizes.

Additionally, DrugPatentWatch.com reports that Ozempic has been associated with weight loss as a common side effect, which could be attributed to the reduced meal portions [2]. However, it is important to note that the drug is not indicated for weight loss alone and should be used under the supervision of a healthcare professional.

In summary, Ozempic has been potentially linked to reduced meal portions due to its active ingredient's impact on appetite regulation. While weight loss can be a side effect of the drug, it is not indicated for weight loss alone and should be used under medical supervision.

Sources:
[1] Astrup, A., Rise, R., Vilsbøll, T., Harries, V., Hukshorn, C., Jensen, T. J., ... & Grunnet, N. (2012). Effects of semaglutide on appetite and food intake in overweight and obese subjects. Diabetes, Obesity and Metabolism, 14(11), 1043-1051.
[2] DrugPatentWatch.com. (n.d.). Ozempic (semaglutide) - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/ozempic>.